OCTANe LaunchPad Company Award

Harbor MedTech Wins OCTANe LaunchPad Award

By Awards, Healthcare Marketing Awards, Medical Marketing

DevicePharm, along with six other Orange County professional services firms, co-sponsored the 2016 OCTANe LaunchPad ‘Company Of The Year’ award. The LaunchPad Program gave nine early-stage companies the opportunity to present to a panel of investors with the chance to receive a bundle of professional services ranging from brand development to intellectual property, reimbursement, and financial services.

Read More
OCTANe Conference - Medical Devices & Investor Forum

DevicePharm CEO Hosts Big Data Panel at 2016 Medical Device and Investor Forum

By Marketing Strategy, Medical Device Marketing, Medical Marketing

Big Data. The term is ubiquitous in our culture and its importance was validated by the attendance of over 500 people at the leadoff panel during the OCTANe 2016 Medical Device and Investor Forum. The panel, titled “Using Big Data To Improve Patient Outcomes and Reimbursement” was hosted by DevicePharm CEO, Clay Wilemon.

Read More
DevicePharm - Medical Device Marketing through the eyes of your customers

Medical Device Marketing Through the Eyes of Your Customers

By Marketing Strategy, Medical Device Marketing, Medical Marketing

Every medical marketer wants to know one thing, “What are my customers thinking?”. On November 10, 2016, DevicePharm and Medical Alley will co-host an event designed to answer that very question. Titled ‘Medical Device Marketing Through the Eyes of Your Customers’, this event will feature a panel that includes surgeons, interventionalists, and hospital and practice executives from the Twin Cities area.

Read More
Agendia Mammaprint - medical advertising materials

46% Of High Risk Breast Cancer Patients May Not Require Chemo

By Articles, Case Studies

Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.

Read More
Christine Horton, Vice President

Christine Horton Joins DevicePharm As Vice President

By Press

Irvine, CA and Minneapolis, MN (August 10, 2016) – DevicePharm, a marketing strategy and integrated marketing communications firm serving medical device, biotech, diagnostics, and pharmaceutical companies, announced today that Christine Horton has joined the firm as Vice President. She will be based in the firm’s rapidly growing Minneapolis office and will serve as a member of the leadership team.

Read More